Bristol/Sanofi To Seek Plavix Indication For Subset Of Heart Attack Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies plan to file a clopidogrel supplemental NDA for prevention of clinical events in patients with a history of acute ST-segment elevation myocardial infarction. The filing is planned by year-end, based on results of the COMMIT and CLARITY studies, Bristol says.
You may also be interested in...
Plavix Label Gets CLARITY On New Indication: Will Bristol COMMIT To Marketing Effort?
FDA approval comes one day before injunction hearing involving Apotex’ clopidogrel generic.
Plavix Label Gets CLARITY On New Indication: Will Bristol COMMIT To Marketing Effort?
FDA approval comes one day before injunction hearing involving Apotex’ clopidogrel generic.
Plavix sNDA Granted Priority Review
Bristol-Myers Squibb's and Sanofi-Aventis' anti-thrombotic Plavix (clopidogrel bisulfate) will have a user fee date of May 17, 2006 under a six-month priority review